HFB30132A

DRUG2 trials

Sponsors

HiFiBiO Therapeutics

Conditions

Healthy

Phase 1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults

CompletedNCT04590430

HiFiBiO TherapeuticsHealthy

Start: 2020-10-20End: 2021-07-26Updated: 2022-03-11

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults

CompletedNCT05275660

HiFiBiO TherapeuticsHealthy

Start: 2021-05-09End: 2022-02-22Updated: 2022-03-11

Related Papers

Population pharmacokinetics and pharmacodynamics of HFB30132A, a monoclonal antibody against SARS-CoV-2, in healthy Chinese and US subjects.

2025-01-09

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Frontiers in Pharmacology2023-05-234 citations